Faculty Profiles - Tanaka Shota

Papers - Tanaka Shota

Division display 101 - 120 of about 213 ／ All the affair displays >>

PATH-10. EFFECTS OF 19q-LOSS IN IDH-MUTATED ASTROCYTOMAS ON BETTER PROGNOSIS AND OLIGODENDROGLIOMA-LIKE MORPHOLOGY

Ryohei Otani, Takeo Uzuka, Fumi Higuchi, Hadzki Matsuda, Shota Tanaka, Akitake Mukasa, Phyo Kim, Keisuke Ueki

Neuro-Oncology 22 ( Supplement_2 ) ii165 - ii166 2020.11

Publishing type：Research paper (scientific journal) Publisher：Oxford University Press (OUP)

Abstract

We previously reported that there was a subgroup of IDH-mutated astrocytomas harboring only 19q-loss showing oligodendroglioma-like morphology and significantly longer overall survival (OS) compared with 19q-intact astrocytomas. To further explore the biological characteristics of this possible subgroup and obtain insight into the mechanism of their clinical behavior, we compared gene expression pattern between five 19q-loss and five 19q-intact IDH-mutated astrocytomas by microarray analysis. Comparing expression level of each genes between 19q-loss and 19q-intact astrocytomas,136 up-regulated genes and 203 down-regulated genes were extracted. Gene expression patterns of 19q-loss astrocytomas were partially different from that of 19q-intact astrocytomas. More down-regulated genes distributed on 19q and 4p, and more up-regulated genes distributed on 4q. Multiple genes associated with stem cell maintenance were down-regulated in 19q-loss astrocytomas, and genes associated with glioma progression were differentially expressed. Comparing expression patterns among 19q-loss astrocytomas and other IDH-mutant glioma subgroups using TCGA datasets by t-SNE analysis revealed that expression pattern of 19q-loss astrocytomas did not shift to that of oligodendrogliomas with 1p/19q codeletion but were a subgroup in astrocytomas. These results indicated that 19q-loss in astrocytomas was an acquired event different from 1p/19q codeletion in oligodendrogliomas, and better prognosis morphological features in 19q-loss astrocytomas were derived from differentially expressed genes associated with stem cell maintenance and glioma progression.

DOI： 10.1093/neuonc/noaa215.692

researchmap

グリオーマを術中標識する新規局所噴霧型蛍光プローブの開発

田中將太, 北川陽介, 高柳俊作, 武笠晃丈, 浦野泰照

日本癌学会総会記事 79回 OE15 - 4 2020.10

神経内視鏡手術:適応・手術手技・合併症回避、そして新たな展開脳室拡大を伴わない小児脳室内腫瘍に対する神経内視鏡手術適応、手術手技、合併症の回避と新たな展開

辛正廣, 田中将太, 高柳俊作, 斉藤延人

小児の脳神経 45 ( 3 ) 214 - 214 2020.10

脊髄上衣腫のエピゲノム解析

山澤恵理香, 田中將太, 永江玄太, 目黒裕子, 梅田高呂, 花大洵, 高見俊宏, 中西勇太, 谷口真, 高井敬介, 小森隆司, 市村幸一, 福岡講平, 高柳俊作, 油谷浩幸, 齋藤延人

日本癌学会総会記事 79回 OE9 - 3 2020.10

グリオーマを術中標識する新規局所噴霧型蛍光プローブの開発

田中將太, 北川陽介, 高柳俊作, 武笠晃丈, 浦野泰照

日本癌学会総会記事 79回 OE15 - 4 2020.10

脊髄上衣腫のエピゲノム解析

日本癌学会総会記事 79回 OE9 - 3 2020.10

Factors associated with health-related quality of life in patients with glioma: impact of symptoms and implications for rehabilitation. Reviewed International journal

Shigeko Umezaki, Yusuke Shinoda, Akitake Mukasa, Shota Tanaka, Shunsaku Takayanagi, Hiroyuki Oka, Hisato Tagawa, Nobuhiko Haga, Mariko Yoshino

Japanese journal of clinical oncology 50 ( 9 ) 990 - 998 2020.9

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: The factors associated with health-related quality of life in patients with glioma remain unclear; particularly, the impact of symptoms on quality of life has not been studied comprehensively. This study aims to document the quality of life of patients with glioma and clarify the impact of symptoms. METHODS: In this cross-sectional study, participants were recruited from patients at The University of Tokyo Hospital and from patients who were registered at the Japan Brain Tumor Alliance. We included adult patients with World Health Organization grade II-IV glioma and excluded those with disturbances of consciousness or aphasia. We used the European Organization for Research and Treatment of Cancer QLQ-C30 and BN20 to evaluate quality of life and the symptoms. Multiple regression analyses were performed to investigate the impact of symptoms on European Organization for Research and Treatment of Cancer global health status and QLQ-C30 social functioning. In addition, we performed univariate subgroup analyses classified by World Health Organization grade and history of chemotherapy. RESULTS: This study included 76 patients. Seven symptoms occurred in more than 50% of the patients: fatigue, future uncertainty, drowsiness, communication deficit, financial difficulties, motor dysfunction and weakness of legs. Multiple regression analyses showed that insomnia affected their global health status, and appetite loss, financial difficulties and motor dysfunction were significantly related to their social functioning. In subgroup analysis, the number of symptom subscales that were significantly related to global health status and social functioning was larger in World Health Organization grade II patients compared with grade III/IV patients. CONCLUSIONS: In addition to neurological deficits, symptoms were associated with poor quality of life in patients with glioma. This study provided the basis on further investigation of usefulness of symptom evaluation on quality of life improvement.

DOI： 10.1093/jjco/hyaa068

PubMed

researchmap

現場最前線覚醒下腫瘍摘出術における言語聴覚士の役割日英米の比較

兼岡麻子, 荻野亜希子, 高柳俊作, 國井尚人, 田中将太, 芳賀信彦

言語聴覚研究 17 ( 3 ) 177 - 180 2020.9

Language：Japanese Publisher：(一社)日本言語聴覚士協会

＜文献概要＞1.はじめに覚醒下腫瘍摘出手術は,脳腫瘍周辺の機能領域に対する損傷を避けつつ,腫瘍を最大限に切除することを目的とした術式で,通常の開頭腫瘍摘出術に比べて腫瘍摘出率,術後後遺症,生命予後の点で優位とされる.言語野近傍の腫瘍に対する覚醒下手術では,術中に患者を覚醒させ,言語タスクを実施する間に患者の脳表に電気刺激を与えてその機能を一時的に低下させ,電気刺激によって誘発または抑制される言語症状から患者の機能領域を同定する(図1).術者はこの皮質マッピングの結果を考慮して腫瘍の切除範囲を決定する.また,言語に関わる神経線維近傍の腫瘍切除術では,脳白質に電気刺激を与えて陽性反応を観察する皮質下マッピングも行われる.本邦では,2012年に日本Awake Surgery学会が世界初の英語版覚醒下手術ガイドラインを,また翌年には日本語版ガイドラインを発表した.さらに,2014年には覚醒下脳手術施設認定制度が始まり,2015年には脳腫瘍覚醒下マッピング加算の算定が可能となった.2016年には全国で105件,2017年には185件の覚醒下腫瘍摘出術が施行され,今後覚醒下手術を行う施設はさらに増えるものと予想される.覚醒下手術は多職種によるチーム医療であり,言語・高次脳機能の専門職として言語聴覚士もその一端を担う.当院においても,2016年より言語聴覚士が覚醒下手術に参加し,術前評価,術中マッピング,術後評価とリハビリテーションを行っている.覚醒下手術は世界的に広く行われているが,各国の覚醒下手術における言語聴覚士の役割を知る機会は少ない.今回,英米の2大学病院に勤務する言語聴覚士とともに,当院を含めた3大学病院の覚醒下手術における言語聴覚士の業務内容を比較し,課題や今後の展望について考察したので報告する.なお,本稿の要旨は,The American Speech-Language-Hearing Association Convention 2019において,各病院の言語聴覚士と共同で発表した.また,言語聴覚士の職名は各国で異なるが(英国:Speech Language Therapist,SLT/米国:Speech Language Pathologist,SLP/日本:Speech Therapist,ST),本稿では便宜上,一律に「言語聴覚士」と記載した.

researchmap

初発膠芽腫におけるMGMTと腫瘍微小環境との関連

串原義啓, 齋藤範之, 手島太郎, 孫長博, 小林由香利, 長岡孝治, 細井亮宏, 唐崎隆弘, 田中將太, 齊藤延人, 垣見和宏

日本がん免疫学会総会プログラム・抄録集 24回 91 - 91 2020.9

高柳俊作, 田中將太, 齊藤延人

脳神経外科速報 30 ( 9 ) 970 - 977 2020.9

Language：Japanese Publisher：(株)メディカ出版

NCCオンコパネルやFoundationOneといった、多数のがん関連遺伝子の異常を一度に解析できるがん遺伝子パネル検査が日本でも保険診療で行えるようになり、わが国のがんゲノム医療体制は急速に整備されてきた。パネル検査により、脳腫瘍領域でも、治療に有用と思われる多数の遺伝子異常が同定できる。例えばEGFR、IDH、H3F3A、HIST1H3B、BRAF遺伝子、NTRK融合遺伝子などである。これらの遺伝子異常に対応した分子標的薬は、現状ではまだまだ少ない状況である。しかし、NTRK融合遺伝子陽性腫瘍に対するエヌトレクチニブは保険承認され、さらにIDH阻害薬やBRAF阻害薬などの臨床試験も行われており、少しずつではあるが、脳腫瘍領域においてもパネル検査結果に基づく個別化医療が推進されていくことが予想される。(著者抄録)

researchmap

Other Link： https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J03120&link_issn=&doc_id=20200826180004&doc_link_id=issn%3D0917-1495%26volume%3D30%26issue%3D9%26spage%3D970&url=http%3A%2F%2Fwww.pieronline.jp%2Fopenurl%3Fissn%3D0917-1495%26volume%3D30%26issue%3D9%26spage%3D970&type=PierOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00005_2.gif

膠芽腫を標識する噴霧式新規蛍光プローブの開発

北川陽介, 田中將太, 神谷真子, 栗木優五, 高柳俊作, 武笠晃丈, 浦野泰照, 齊藤延人

日本レーザー医学会誌 41 ( 3 ) 277 - 277 2020.9

脳腫瘍の遺伝子診断とゲノム医療2 19q-lossを伴うastrocytomaが予後良好である機序の解明

大谷亮平, 宇塚岳夫, 樋口芙未, 松田葉月, 田中将太, 金彪, 植木敬介

Brain Tumor Pathology 37 ( Suppl. ) 075 - 075 2020.8

家族性腫瘍(遺伝性腫瘍)における脳腫瘍遺伝性腫瘍疾患における脳腫瘍の病理と遺伝子解析

高柳俊作, 高見浩数, 田中将太, 寺西裕, 宮脇哲, 辛正廣, 中冨浩文, 池村雅子, 織田克利, 齊藤延人

Brain Tumor Pathology 37 ( Suppl. ) 078 - 078 2020.8

脳腫瘍の遺伝子診断とゲノム医療1 IDH wildtype LGGにおける最も重要な予後不良因子はTERT promoter mutationである

藤本健二, 有田英之, 金村米博, 田中將太, 永根基雄, 植木敬介, 西川亮, 小森隆司, 成田善孝, 市村幸一

Brain Tumor Pathology 37 ( Suppl. ) 065 - 065 2020.8

家族性腫瘍(遺伝性腫瘍)における脳腫瘍遺伝性腫瘍疾患における脳腫瘍の病理と遺伝子解析

高柳俊作, 高見浩数, 田中将太, 寺西裕, 宮脇哲, 辛正廣, 中冨浩文, 池村雅子, 織田克利, 齊藤延人

Brain Tumor Pathology 37 ( Suppl. ) 078 - 078 2020.8

脳腫瘍の遺伝子診断とゲノム医療2 19q-lossを伴うastrocytomaが予後良好である機序の解明

大谷亮平, 宇塚岳夫, 樋口芙未, 松田葉月, 田中将太, 金彪, 植木敬介

Brain Tumor Pathology 37 ( Suppl. ) 075 - 075 2020.8

Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Reviewed International journal

Shota Tanaka, Iori Sato, Masamichi Takahashi, Terri S Armstrong, Charles S Cleeland, Tito R Mendoza, Akitake Mukasa, Shunsaku Takayanagi, Yoshitaka Narita, Kiyoko Kamibeppu, Nobuhito Saito

Japanese journal of clinical oncology 50 ( 7 ) 787 - 793 2020.7

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: The MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) module is a widely used instrument for measuring symptom burden and interference of daily activities in brain tumor patients. This study aims to develop and validate its Japanese version (MDASI-BT-Japanese). METHODS: Following forward and backward translation of the original MDASI-BT into Japanese, understandability and feasibility were assessed by cognitive debriefing. Subsequently, patients with brain tumors were asked to fill out MDASI-BT-Japanese and European Quality of Life-5 Dimensions (EQ-5D). Feasibility, reliability and validity of MDASI-BT-Japanese were assessed. RESULTS: Cognitive debriefing confirmed overall ease of completion and good understandability. The study population composed of 140 patients with brain tumors (most commonly gliomas). The mean symptom severity score and mean interference score were 1.9 ± 1.7 and 2.8 ± 2.7, respectively. The top items included distress and drowsiness for symptom severity and general activity and work for interference. The median time required was 4 minutes (range, 0.5-30), and missing values were seen in 1%. Internal consistency was proven by excellent Cronbach's coefficient alpha (0.94 for symptom severity, 0.92 for interference). Test-retest reliability was assessed with acceptable intra-class correlation coefficient (mean, 0.76). Correlation efficient ranged between 0.7 and 0.9 for convergent validity. Known-group validity was confirmed by significantly different mean symptom severity score and mean interference score among patients with different performance status. As evidence of concurrent validity, MDASI-BT-Japanese correlated with EQ-5D in the hypothesized magnitude and direction. CONCLUSIONS: The newly developed MDASI-BT-Japanese has demonstrated feasibility, reliability and validity in evaluation of clinical benefit in Japanese-speaking brain tumor patients.

DOI： 10.1093/jjco/hyaa036

PubMed

researchmap

Small Cell Variant of Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma of the Dura Mimicking Tentorial Meningioma. Reviewed International journal

Yudai Hirano, Satoru Miyawaki, Michiaki Satou, Kazuki Taoka, Kazuhiro Toyama, Masako Ikemura, Ryo Tanaka, Shunsaku Takayanagi, Shota Tanaka, Hirofumi Nakatomi, Mineo Kurokawa, Nobuhito Saito

World neurosurgery 138 169 - 173 2020.6

Language：English

BACKGROUND: Primary central nervous system (CNS) anaplastic large cell lymphoma (ALCL) is an uncommon type of brain tumor, usually treated with a regimen that includes high-dose methotrexate (MTX). Only a few cases of primary CNS anaplastic lymphoma kinase (ALK)-positive ALCL have been reported so far, with no reported cases of a small cell variant. CASE DESCRIPTION: A 26-year-old man presenting with headache and visual field impairment was found to have a supratentorial mass mimicking meningioma. Craniotomy was performed for tumor resection, and postoperative histologic examination revealed atypical cells that were nonenlarged lymphocytes with irregularly shaped and enlarged nuclei; these cells were cluster of differentiation 30 and ALK-positive, leading to the diagnosis of a small cell variant of ALK-positive ALCL. In this case, the tumor exhibited an aggressive behavior with MTX resistance with metastases in the pelvis but responded well to cytarabine and etoposide (CYVE). CONCLUSIONS: In general, CNS ALK-positive ALCL responds well to MTX, but small cell variants show aggressive behavior and may be resistant to MTX. For small cell variants of ALCL that are resistant to MTX therapy, as in this case, CYVE therapy may be an effective treatment.

DOI： 10.1016/j.wneu.2020.02.171

PubMed

researchmap

Increased Vascular Adhesion Protein 1 (VAP-1) Levels are Associated with Alternative M2 Macrophage Activation and Poor Prognosis for Human Gliomas. International journal

Shu-Jyuan Chang, Hung-Pin Tu, Yen-Chang Clark Lai, Chi-Wen Luo, Takahide Nejo, Shota Tanaka, Chee-Yin Chai, Aij-Lie Kwan

Diagnostics (Basel, Switzerland) 10 ( 5 ) 2020.4

Language：English Publishing type：Research paper (scientific journal)

Glioma is characterized by a high heterogeneity in the brain tumor. Abundant tumor-associated macrophages (TAMs) exist as neoplastic tissues, implicating tumor plasticity and thus leading to therapeutic challenges. Vascular adhesion protein (VAP-1) potentially serves as a mediator for TAM immunity in tumor milieu. We previously demonstrated that VAP-1 could contribute to tumor malignancy, but its characteristics in TAM immunity of glioma progression are still unclear. This study explored the association of VAP-1 expression with TAM distribution as well as the resulting clinical significance and prognostic value in human gliomas. An in-depth analysis of AOC3 (VAP-1) gene expression was performed using 695 glioma samples derived from the cancer genome atlas (TCGA)-lower grade glioma and glioblastoma (GBMLGG) cohort. Bioinformatic analysis confirmed that VAP-1 expression is associated with poor prognosis of glioma patients (p = 0.0283). VAP-1 and TAM biomarkers (CD68, iNOS, and CD163) were evaluated by immunohistochemistry in 108 gliomas from Kaohsiung Medical University Hospital. VAP-1+ was expressed in 56 (51.85%) cases and this phenotype revealed a significant association with overall survival in Kaplan-Meier analysis (p < 0.0001). Immunohistochemical double staining showed that VAP-1 immunoreactivity was present around CD163+ M2 infiltration location, including aggressive lesions and neighboring neovasculature. We demonstrated that high VAP-1 expression levels positively correlated with CD163+ M2 activation and coexpression of these two proteins was associated with worse survival in gliomas (p < 0.0001). Multivariate analysis indicated that VAP-1 alone and co-expressed with CD163 were the significantly independent indicators (both p < 0.0001). Furthermore, VAP-1/CD163 coexpression exhibited excellent diagnostic accuracy in gliomas (AUC = 0.8008). In conclusion, VAP-1 and TAM CD163 M2 coexpression was found in glioma tissues belonging to a highly malignant subgroup that was associated with poor prognosis. These results implied VAP-1 abundance is closely linked to alternative M2 activation during glioma progression. From the aforementioned data, a reasonable inference is that VAP-1 combined with targeting M2 immunity might be an effective therapeutic target for human gliomas.

DOI： 10.3390/diagnostics10050256

PubMed

researchmap

Publisher Correction: Prediction of malignant glioma grades using contrast-enhanced T1-weighted and T2-weighted magnetic resonance images based on a radiomic analysis. International journal

Takahiro Nakamoto, Wataru Takahashi, Akihiro Haga, Satoshi Takahashi, Shigeru Kiryu, Kanabu Nawa, Takeshi Ohta, Sho Ozaki, Yuki Nozawa, Shota Tanaka, Akitake Mukasa, Keiichi Nakagawa

Scientific reports 10 ( 1 ) 3073 - 3073 2020.2

　 PREV - NEXT 　

< Tanaka Shota >

Papers - Tanaka Shota